• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

系统性硬化症亚型的分类标准。

Classification criteria for systemic sclerosis subsets.

作者信息

Johnson Sindhu R, Feldman Brian M, Hawker Gillian A

机构信息

Division of Rheumatology, University Health Network, University of Toronto, Toronto, Ontario, Canada.

出版信息

J Rheumatol. 2007 Sep;34(9):1855-63. Epub 2007 Aug 1.

PMID:17696271
Abstract

OBJECTIVE

To evaluate the measurement properties of criteria for systemic sclerosis (SSc) subsets for classification of patients in SSc trials, and to determine if any one criteria set confers measurement advantage over others.

METHODS

A systematic review of articles describing classification criteria for SSc subsets was performed. Evidence supporting the sensibility (statement of purpose for which the criteria will be used, population, setting, face and content validity, and feasibility), validity, and reliability of the criteria was evaluated.

RESULTS

Fourteen sets of criteria for SSc subsets were identified. There is variability in the intended purpose and setting for which criteria sets are to be applied. Although face validity improves with the addition of less commonly encountered subsets or disease manifestations as criteria, the feasibility of implementing such criteria is conversely limited. Content validity for most criteria sets has not been evaluated due to lack of an explicitly stated conceptual framework for SSc. The criteria with 3 or more subsets do not provide incremental predictive validity over the 2-subset criteria. Our ability to compare subset criteria on divergent validity and reliability is limited by a lack of data.

CONCLUSION

The 2-subset criteria of LeRoy, et al have good feasibility, acceptable face validity, and good predictive validity. Further research is needed to compare the content validity, divergent validity, and reliability of these with other subset criteria for use in SSc trials.

摘要

目的

评估系统性硬化症(SSc)亚组分类标准在SSc试验中对患者分类的测量属性,并确定是否有任何一套标准在测量方面比其他标准更具优势。

方法

对描述SSc亚组分类标准的文章进行系统综述。评估支持这些标准的敏感性(标准使用目的、人群、背景、表面效度和内容效度以及可行性的陈述)、效度和信度的证据。

结果

确定了14套SSc亚组标准。各套标准的预期用途和应用背景存在差异。虽然随着将较少见的亚组或疾病表现作为标准加入,表面效度有所提高,但实施此类标准的可行性却相反受到限制。由于缺乏明确阐述的SSc概念框架,大多数标准集的内容效度尚未得到评估。具有3个或更多亚组的标准相对于2个亚组的标准并未提供额外的预测效度。由于缺乏数据,我们在比较不同效度和信度的亚组标准方面的能力受到限制。

结论

LeRoy等人的2个亚组标准具有良好的可行性、可接受的表面效度和良好的预测效度。需要进一步研究以比较这些标准与其他用于SSc试验的亚组标准的内容效度、区分效度和信度。

相似文献

1
Classification criteria for systemic sclerosis subsets.系统性硬化症亚型的分类标准。
J Rheumatol. 2007 Sep;34(9):1855-63. Epub 2007 Aug 1.
2
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
3
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
4
The measurement and monitoring of surgical adverse events.手术不良事件的测量与监测
Health Technol Assess. 2001;5(22):1-194. doi: 10.3310/hta5220.
5
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
6
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
7
Comparison of cellulose, modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal disease.纤维素、改性纤维素和合成膜在终末期肾病患者血液透析中的比较。
Cochrane Database Syst Rev. 2001(3):CD003234. doi: 10.1002/14651858.CD003234.
8
Psychological and/or educational interventions for the prevention of depression in children and adolescents.预防儿童和青少年抑郁症的心理和/或教育干预措施。
Cochrane Database Syst Rev. 2004(1):CD003380. doi: 10.1002/14651858.CD003380.pub2.
9
Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.吸入装置在哮喘和慢性阻塞性气道疾病中的有效性比较:文献系统评价
Health Technol Assess. 2001;5(26):1-149. doi: 10.3310/hta5260.
10
Cyclophosphamide for connective tissue disease-associated interstitial lung disease.环磷酰胺用于治疗结缔组织病相关的间质性肺疾病。
Cochrane Database Syst Rev. 2018 Jan 3;1(1):CD010908. doi: 10.1002/14651858.CD010908.pub2.

引用本文的文献

1
Advanced Autoantibody Testing in Systemic Sclerosis.系统性硬化症中的高级自身抗体检测
Diagnostics (Basel). 2023 Feb 23;13(5):851. doi: 10.3390/diagnostics13050851.
2
Early Diagnosis of Systemic Sclerosis: The Role of General Practitioner.系统性硬化症的早期诊断:全科医生的作用
Cureus. 2022 Dec 7;14(12):e32291. doi: 10.7759/cureus.32291. eCollection 2022 Dec.
3
The promise of precision medicine in rheumatology.精准医学在风湿病学中的前景。
Nat Med. 2022 Jul;28(7):1363-1371. doi: 10.1038/s41591-022-01880-6. Epub 2022 Jul 4.
4
Flow cytometry evaluation of CD14/CD16 monocyte subpopulations in systemic sclerosis patients: a cross sectional controlled study.流式细胞术评估系统性硬化症患者 CD14/CD16 单核细胞亚群:一项横断面对照研究。
Adv Rheumatol. 2021 May 22;61(1):27. doi: 10.1186/s42358-021-00182-8.
5
Systematic Analysis of the Literature in Search of Defining Systemic Sclerosis Subsets.系统性红斑狼疮亚型的文献系统性分析。
J Rheumatol. 2021 Nov;48(11):1698-1717. doi: 10.3899/jrheum.201594. Epub 2021 May 15.
6
Prevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review and meta-analysis.系统性硬化症中小肠细菌过度生长的患病率和预测因素:系统评价和荟萃分析。
Clin Rheumatol. 2021 Aug;40(8):3039-3051. doi: 10.1007/s10067-020-05549-8. Epub 2021 Jan 11.
7
Systemic sclerosis: To subset or not to subset, that is the question.系统性硬化症:是否进行亚组分析,这是个问题。
Eur J Rheumatol. 2020 Oct;7(Suppl 3):S222-S227. doi: 10.5152/eurjrheum.2020.19116. Epub 2020 Jul 6.
8
T6746C and P72R Polymorphisms Are Associated with the Susceptibility to Diffuse Cutaneous Systemic Sclerosis.T6746C 和 P72R 多态性与弥漫性皮肤系统性硬皮病的易感性相关。
Biomed Res Int. 2020 Feb 25;2020:8465971. doi: 10.1155/2020/8465971. eCollection 2020.
9
New ACR EULAR guidelines for systemic sclerosis classification.新版 ACR/EULAR 系统性硬化症分类标准。
Curr Rheumatol Rep. 2015 May;17(5):32. doi: 10.1007/s11926-015-0506-3.
10
[The road to early diagnosis of systemic sclerosis : the evolution of diagnostic and classification criteria in the past decades].[系统性硬化症的早期诊断之路:过去几十年诊断及分类标准的演变]
Z Rheumatol. 2013 Dec;72(10):954-9. doi: 10.1007/s00393-013-1194-x.